期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 62, 期 10, 页码 677-683出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2007.12.008
关键词
(-)-Epigallocatechin-3-gallate (EGCG); Cholesterol gallstone; Anti-inflammation effect; Cholesterol metabolic
In order to investigate whether (-)-Epigallocatechin-3-gallate (EGCG) can reduce the susceptibility to cholesterol gallstone formation in vivo, cholesterol gallstones mouse model was established with lithogenic diet. Compared with the Model group, the administration of EGCG (40 mg kg(-1) d(-1) and 80 mg kg(-1) d(-1), i.g., respectively) significantly reduced the gallstone formation rates and the serum lipid levels, also maintained the body weight at a relatively low level. Results of the microarray profiling assay showed the anti-inflammation effect of EGCG underlying affecting the hepatic metabolic pathway of cholesterol. Additionally, the expression of nuclear factor-kappa B (NF-kappa B) was down-regulated and the expression of peroxisome proliferator activated receptor gamma (PPAR gamma) was up-regulated after the treatment of EGCG. Also, the expression of CYP7A1 was up-regulated after the treatment of EGCG. In conclusion, the findings of this study implied that EGCG can effectively reduce the susceptibility to cholesterol gallstone formation through the regulation of inflammation. (c) 2007 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据